Titre : Bandes oligoclonales

Bandes oligoclonales : Questions médicales fréquentes

Termes MeSH sélectionnés :

Attention Deficit and Disruptive Behavior Disorders
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Bandes oligoclonales : Questions médicales les plus fréquentes", "headline": "Bandes oligoclonales : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Bandes oligoclonales : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-15", "dateModified": "2025-04-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Bandes oligoclonales" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Marqueurs biologiques", "url": "https://questionsmedicales.fr/mesh/D015415", "about": { "@type": "MedicalCondition", "name": "Marqueurs biologiques", "code": { "@type": "MedicalCode", "code": "D015415", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.101" } } }, "about": { "@type": "MedicalCondition", "name": "Bandes oligoclonales", "alternateName": "Oligoclonal Bands", "code": { "@type": "MedicalCode", "code": "D043025", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Luisa María Villar", "url": "https://questionsmedicales.fr/author/Luisa%20Mar%C3%ADa%20Villar", "affiliation": { "@type": "Organization", "name": "Ramon y Cajal Hospital of Madrid, Spain." } }, { "@type": "Person", "name": "Wei Qiu", "url": "https://questionsmedicales.fr/author/Wei%20Qiu", "affiliation": { "@type": "Organization", "name": "Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Electronic address: qiuwei120@vip.163.com." } }, { "@type": "Person", "name": "Alexander Y Lau", "url": "https://questionsmedicales.fr/author/Alexander%20Y%20Lau", "affiliation": { "@type": "Organization", "name": "Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: alexlau@cuhk.edu.hk." } }, { "@type": "Person", "name": "Hongjun Hao", "url": "https://questionsmedicales.fr/author/Hongjun%20Hao", "affiliation": { "@type": "Organization", "name": "Department of Neurology, Neuroimmunology Laboratory, Peking University First Hospital, Beijing, China." } }, { "@type": "Person", "name": "Carmen M Cabrera", "url": "https://questionsmedicales.fr/author/Carmen%20M%20Cabrera", "affiliation": { "@type": "Organization", "name": "Immunology Section, University General Hospital of Ciudad Real, Ciudad Real, Spain; Faculty of Medicine of Ciudad Real, University of Castilla-La Mancha, Ciudad Real, Spain. Electronic address: carmenmcabrera@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Exploring real-time functional magnetic resonance imaging neurofeedback in adolescents with disruptive behavior disorder and callous unemotional traits.", "datePublished": "2023-10-16", "url": "https://questionsmedicales.fr/article/37852585", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jad.2023.10.036" } }, { "@type": "ScholarlyArticle", "name": "The conduct and oppositional defiant disorder scales (CODDS) for disruptive behaviour disorders.", "datePublished": "2022-07-23", "url": "https://questionsmedicales.fr/article/35961152", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.psychres.2022.114744" } }, { "@type": "ScholarlyArticle", "name": "Short-Term Impact of \"Amaka Amasanyufu\" Multiple Family Group Intervention on Mental Health Functioning of Children With Disruptive Behavior Disorders in Uganda.", "datePublished": "2023-03-08", "url": "https://questionsmedicales.fr/article/36898607", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jaac.2022.12.028" } }, { "@type": "ScholarlyArticle", "name": "Some critical comments on the paper titled \"Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders\".", "datePublished": "2022-10-21", "url": "https://questionsmedicales.fr/article/36328895", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.cpr.2022.102214" } }, { "@type": "ScholarlyArticle", "name": "Polygenic risk scores for antisocial behavior in relation to amygdala morphology across an attention deficit hyperactivity disorder case-control sample with and without disruptive behavior.", "datePublished": "2022-07-30", "url": "https://questionsmedicales.fr/article/35914510", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.euroneuro.2022.07.182" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Marqueurs biologiques", "item": "https://questionsmedicales.fr/mesh/D015415" }, { "@type": "ListItem", "position": 4, "name": "Bandes oligoclonales", "item": "https://questionsmedicales.fr/mesh/D043025" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Bandes oligoclonales - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Bandes oligoclonales", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-11", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Bandes oligoclonales", "description": "Comment détecte-t-on les bandes oligoclonales ?\nQuelles maladies sont associées aux bandes oligoclonales ?\nQuel est le rôle des bandes oligoclonales dans le diagnostic ?\nLes bandes oligoclonales sont-elles toujours présentes dans les maladies ?\nQuel test est utilisé pour analyser les bandes oligoclonales ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Bandes oligoclonales", "description": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?\nLes bandes oligoclonales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les maladies ?\nLes symptômes sont-ils toujours présents avec des bandes oligoclonales ?\nQuels tests neurologiques complètent l'analyse des bandes ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Bandes oligoclonales", "description": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?\nQuels facteurs de risque sont associés aux maladies neurologiques ?\nL'alimentation influence-t-elle le risque de maladies neurologiques ?\nLe stress a-t-il un impact sur ces maladies ?\nDes vaccinations peuvent-elles prévenir ces maladies ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Bandes oligoclonales", "description": "Quel traitement est recommandé pour les maladies associées ?\nLes bandes oligoclonales nécessitent-elles un traitement direct ?\nQuels médicaments sont utilisés pour la sclérose en plaques ?\nLes traitements sont-ils efficaces contre les bandes ?\nY a-t-il des traitements expérimentaux pour ces conditions ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Bandes oligoclonales", "description": "Quelles complications peuvent survenir avec la sclérose en plaques ?\nLes bandes oligoclonales entraînent-elles des complications ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications à long terme des maladies neurologiques ?\nLes complications sont-elles réversibles ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Bandes oligoclonales", "description": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?\nLe tabagisme est-il un facteur de risque ?\nL'exposition à des virus influence-t-elle le risque ?\nLe climat joue-t-il un rôle dans le risque de sclérose en plaques ?\nL'activité physique peut-elle réduire le risque ?", "url": "https://questionsmedicales.fr/mesh/D043025?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on les bandes oligoclonales ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont détectées par électrophorèse du liquide céphalorachidien." } }, { "@type": "Question", "name": "Quelles maladies sont associées aux bandes oligoclonales ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont souvent liées à la sclérose en plaques et d'autres maladies neurologiques." } }, { "@type": "Question", "name": "Quel est le rôle des bandes oligoclonales dans le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles aident à confirmer des diagnostics neurologiques en indiquant une réponse immunitaire." } }, { "@type": "Question", "name": "Les bandes oligoclonales sont-elles toujours présentes dans les maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Non, leur présence n'est pas systématique et dépend de la maladie et de son stade." } }, { "@type": "Question", "name": "Quel test est utilisé pour analyser les bandes oligoclonales ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'électrophorèse sur gel est couramment utilisée pour analyser les bandes oligoclonales." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer la présence de bandes oligoclonales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes neurologiques comme des troubles de la vision ou des engourdissements." } }, { "@type": "Question", "name": "Les bandes oligoclonales causent-elles des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles sont un indicateur de maladie, mais ne causent pas de symptômes directement." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les maladies ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon la maladie sous-jacente, comme la sclérose en plaques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents avec des bandes oligoclonales ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Pas nécessairement, certaines personnes peuvent avoir des bandes sans symptômes visibles." } }, { "@type": "Question", "name": "Quels tests neurologiques complètent l'analyse des bandes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des IRM et des tests neurologiques peuvent compléter l'analyse des bandes oligoclonales." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux bandes oligoclonales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un mode de vie sain peut aider." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés aux maladies neurologiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs comme l'âge, le sexe et des antécédents familiaux peuvent augmenter le risque." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le risque de maladies neurologiques ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut réduire le risque, mais des études sont nécessaires." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur ces maladies ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver les symptômes, mais son rôle exact dans la maladie est complexe." } }, { "@type": "Question", "name": "Des vaccinations peuvent-elles prévenir ces maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiques pour prévenir les maladies associées." } }, { "@type": "Question", "name": "Quel traitement est recommandé pour les maladies associées ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements varient, mais incluent souvent des immunomodulateurs pour la sclérose en plaques." } }, { "@type": "Question", "name": "Les bandes oligoclonales nécessitent-elles un traitement direct ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Non, elles ne nécessitent pas de traitement direct, mais indiquent une maladie à traiter." } }, { "@type": "Question", "name": "Quels médicaments sont utilisés pour la sclérose en plaques ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme l'interféron et le natalizumab sont couramment utilisés." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces contre les bandes ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements visent la maladie sous-jacente, pas les bandes elles-mêmes." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour ces conditions ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour certaines maladies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la sclérose en plaques ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles de la mobilité, de la vision et des fonctions cognitives." } }, { "@type": "Question", "name": "Les bandes oligoclonales entraînent-elles des complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles ne causent pas de complications directement, mais indiquent une maladie à risque." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent réduire la qualité de vie en limitant les activités quotidiennes et sociales." } }, { "@type": "Question", "name": "Y a-t-il des complications à long terme des maladies neurologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme peuvent inclure des handicaps physiques et cognitifs." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque pour la sclérose en plaques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe féminin, et des antécédents familiaux de la maladie." } }, { "@type": "Question", "name": "Le tabagisme est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est associé à un risque accru de développer des maladies neurologiques." } }, { "@type": "Question", "name": "L'exposition à des virus influence-t-elle le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections virales, comme le virus d'Epstein-Barr, peuvent augmenter le risque." } }, { "@type": "Question", "name": "Le climat joue-t-il un rôle dans le risque de sclérose en plaques ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études montrent que le risque est plus élevé dans les régions éloignées de l'équateur." } }, { "@type": "Question", "name": "L'activité physique peut-elle réduire le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Une activité physique régulière peut contribuer à réduire le risque de maladies neurologiques." } } ] } ] }

Sources (10000 au total)

Exploring real-time functional magnetic resonance imaging neurofeedback in adolescents with disruptive behavior disorder and callous unemotional traits.

Adolescents with increased callous unemotional traits (CU traits) in the context of disruptive behavior disorder (DBD) show a persistent pattern of antisocial behavior with shallow affect and a lack o... In this explorative randomized controlled trial we randomly assigned twenty-seven adolescents with DBD to individualized real-time functional magnetic resonance neurofeedback (rtfMRI-NF) or behavioral... The rtfMRI-NF (n = 11) and TAU (n = 10) completers showed comparable and significant clinical improvement indicating neither superiority nor inferiority of rtfMRI-NF. The exploratory LMM revealed succ... This exploratory study demonstrated feasibility and suggests clinical efficacy of individualized rtfMRI-NF comparable to active TAU for adolescents with DBD and increased CU traits. Further studies ar...

The conduct and oppositional defiant disorder scales (CODDS) for disruptive behaviour disorders.

This study evaluates the clinical validity of a five-minute instrument, the Conduct and Oppositional Defiant Disorder Scales (CODDS), for assessing oppositional defiant disorder (ODD) and conduct diso...

Short-Term Impact of "Amaka Amasanyufu" Multiple Family Group Intervention on Mental Health Functioning of Children With Disruptive Behavior Disorders in Uganda.

We evaluate the mid-intervention (8 weeks) and short-term (16 weeks) impact of a culturally adapted multiple family group (MFG) intervention, "Amaka Amasanyufu," on the mental health of children with ... We analyzed data from the Strengthening mental health and research training in Sub-Saharan Africa (SMART) Africa-Uganda study. Schools were randomized to the following: a control group; an MFG facilit... There were significant group-by-time interactions for all outcomes, and differences were observed mid-intervention, with short-term effects at 16 weeks (end-intervention). MFG-PP and MFG-CHW children ... Amaka Amasanyufu MFG intervention is effective for reducing depressive symptoms and improving self-concept among children with DBDs while reducing parental stress and mental health problems among care... SMART Africa (Strengthening Mental Health Research and Training); https://clinicaltrials.gov/: NCT03081195....

Some critical comments on the paper titled "Some critical considerations in applying the construct of psychopathy to research and classification of childhood disruptive behavior disorders".

Frick (2022) presented a narrative review of some literature and made several critical comments regarding the extension of the full psychopathy construct to research and classification of childhood di...

Polygenic risk scores for antisocial behavior in relation to amygdala morphology across an attention deficit hyperactivity disorder case-control sample with and without disruptive behavior.

Antisocial and aggressive behaviors show considerable heritability and are central to disruptive behavior disorders (DBDs), but are also frequently observed in attention deficit hyperactivity disorder...

Differential Effects of Disruptive Mood Dysregulation Disorder Comorbidity in Attention Deficit Hyperactivity Disorder on Social Cognition and Empathy.

This study aimed to investigate social cognition and empathy properties in children among Disruptive Mood Dysregulation Disorder (DMDD) + Attention and Hyperactivity Disorder(ADHD); ADHD and healthy c... Twenty-two children with DMDD were compared to matched 30 children with ADHD and 60 healthy controls. We administered Affective Reactivity Index (ARI), KaSi Empathy Scale, Kiddie-SADS, and Reading Min... DMDD + ADHD group had lower performance in ToM skills and empathy than in two groups. The ARI scores were found to be statistically significantly higher in the DMDD group than in two groups. It was al... These results might be important to understand the difficulties in social functioning and interpersonal relationship in children with DMDD and ADHD. Children with DMDD may attend specific therapeutic ...

Language and reading in attention-deficit/hyperactivity disorder and comorbid attention-deficit/hyperactivity disorder + developmental language disorder.

The current study sought to examine whether psycholinguistic assessments could discriminate children and adolescents with developmental language disorder (DLD) from those with attention-deficit/hypera... The Clinical Evaluation of Language Fundamentals-Screening Test (CELFST; Wiig et al., 2013), the Comprehensive Test of Phonological Processing (... The presence of a language disorder (with or without ADHD) predicted poor performance across tasks. Children and adolescents with ADHD (combined vs. inattentive) only significantly differed in sight w... The combination of comorbid ADHD + DLD did not appear to be associated with lower language abilities, sight word reading, or phonemic decoding relative to DLD alone. Reading efficiency was effective i...

Sleep disturbance in children with attention-deficit hyperactivity disorder: relationship with melatonin and behavior.

To evaluate the prevalence and types of sleep problems and their correlations with melatonin content and behavior in Attention-Deficit Hyperactivity Disorder (ADHD) children.... Sleep in ADHD children and typically developing children (TD) aged 6-14 was assessed by the Sleep Disorders Scale for Children (SDSC) and actigraphy, salivary melatonin quantified by ELISA, and behavi... ADHD children showed a higher frequency of sleep disturbances, higher sleep latency, and lower sleep efficiency than in the TD group. The ADHD group presented lower melatonin nocturnal content compare... This study provides, for the first time, evidence that among the frequent sleep disturbances in ADHD, the disorders in initiating and maintaining sleep are associated with the low levels of melatonin ...